Shire plc has published its third Corporate Responsibility Report www.shire.com/shire/financialReports/crr2005/. Shire is a global pharmaceutical company, serving the needs of specialist doctors and their patients. A FTSE 100 company, UK’s third largest drug company and one of the fastest growing pharmaceutical companies, Shire has operations worldwide.
Shire focuses on providing treatment in key therapeutic areas: central nervous system disorders (CNS) including Attention Deficit Hyperactivity Disorder (ADHD) and epilepsy; human genetic therapies including Fabrey Disease and Hunter Syndrome; gastro-intestinal disorders including ulcerative colitis and Crohn’s Disease, and kidney problems including hyperphosphataemia.
Corporate Responsibility has always been at the heart of all of Shire’s activities; in this year’s report Shire talks about issues that are specific to the pharmaceutical industry. These include: drug safety and quality management of products, responsible marketing practices and the more routine aspects of how people are managed and motivated, supply chain and environmental practises as well as describing Shire’s involvement in the local community. You can read about how Shire:
manages drug testing and clinical trials;
ensures responsible marketing of its ADHD drugs;
worked with the Canadian regulators to restore a product to market;
integrated new employees and retained key talent following a major acquisition; and
improved workplace safety and reduced accidents by 50%
The Report can be accessed here or hard copies on e-mail request at cr@shire.com or by telephoning Shire’s Corporate Communications on +44 (0) 1256 894601
Visit www.CorporateRegister.com to access this publication together with a further 11,500 CSR reports.
